InsidersTradesSigma
Track the Editas Medicine, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Editas Medicine, Inc. has recorded 155 insider filings. Market capitalisation: €485.3m. The latest transaction was filed on 4 September 2026 (Cession). Among the most active insiders: Eaton Bruce. The full history is free.
155
Insider Decl.
n/a
Thresholds
€235,203
30 ops.
Buy Volume
€2m
70 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Editas Medicine, Inc. Buy (bullish), based on 9 analysts. Average price target: US$6.00.
51Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 4 September 2026
Declarations155 total
5,124 shares@ US$3.0372Common StockSEC:0001742084-26-000003:0
453 shares@ US$3.0372Common StockSEC:0002063082-26-000006:0
709 shares@ US$3.0372Common StockSEC:0001985604-26-000003:0
700 shares@ US$3.280.0005% mcap1.8% of flowCommon StockSEC144:0001650664-26-000085
5,100 shares@ US$3.280.0034% mcap5.5% of flowCommon StockSEC144:0001650664-26-000087
678 shares@ US$2.580.0004% mcap20.3% of flowCommon StockSEC:0002063082-26-000003:0
4,928 shares@ US$2.670.0033% mcap10.7% of flowCommon StockSEC:0001650664-26-000076:0
5,500 shares@ US$2.880.0036% mcap14.5% of flowCommon StockSEC144:0001650664-26-000074
731 shares@ US$2.70110.0004% mcap2.6% of flowCommon StockSEC:0001650664-26-000055:0
15,380 shares@ US$2.70110.0086% mcap18.8% of flowCommon StockSEC:0001650664-26-000056:0
464 shares@ US$2.7010.0003% mcap100.0% of flowCommon StockSEC:0001650664-26-000057:0
749 shares@ US$2.01961.6% of flowCommon StockSEC:0001650664-26-000006:0
5,394 shares@ US$2.01973.8% of flowCommon StockSEC:0001650664-26-000009:0
474 shares@ US$2.0213.8% of flowCommon StockSEC:0001650664-26-000007:0
713 shares@ US$2.15311.6% of flowCommon StockSEC:0001650664-25-000163:0
5,603 shares@ US$2.15314.4% of flowCommon StockSEC:0001650664-25-000162:0
461 shares@ US$2.153116.6% of flowCommon StockSEC:0001650664-25-000161:0
710 shares@ US$2.59612.0% of flowCommon StockSEC:0001650664-25-000143:0
458 shares@ US$2.596123.9% of flowCommon StockSEC:0001650664-25-000142:0
5,592 shares@ US$2.59615.5% of flowCommon StockSEC:0001650664-25-000141:0
679 shares@ US$2.5846.1% of flowCommon StockSEC:0001650664-25-000118:0
5,121 shares@ US$2.491114.3% of flowCommon StockSEC:0001650664-25-000113:0
446 shares@ US$1.72438.5% of flowCommon StockSEC:0001650664-25-000093:0
726 shares@ US$1.72431.6% of flowCommon StockSEC:0001650664-25-000091:0
15,192 shares@ US$1.724310.8% of flowCommon StockSEC:0001650664-25-000089:0
25 of 155 declarations
关于 Editas Medicine, Inc.
Editas Medicine, Inc. 是一家美国生物技术公司，在美国纳斯达克上市。公司总部位于马萨诸塞州剑桥，在科罗拉多州博尔德设有运营基地，专注于高度创新且波动性大的基因编辑领域。公司成立于2013年，最初名为 Gengine, Inc.，同年更名为 Editas Medicine。公司的核心业务与 CRISPR 科学紧密相关，致力于将 CRISPR/Cas9 和 CRISPR/Cas12a 基因组编辑系统转化为治疗方案。([editasmedicine.com](https://www.editasmedicine.com/about/?utm_source=openai)) Editas 仍被最好地描述为一家临床阶段、商业化前生物技术公司，而非一家创收的制药企业。其价值主张取决于科学执行、监管里程碑和最终商业化，而非当前产品销售。公司的研发管线专注于治疗选择有限的严重疾病的变革性药物。其主要的体内候选药物是 EDIT-401，旨在治疗高脂血症，而 EDIT-301 是一种体外基因编辑项目，正在开发用于镰状细胞病等血液系统疾病。在公司发展的早期阶段，Editas 还在眼科领域推进了 EDIT-101，这突显了其平台方法的广度。([editasmedicine.com](https://www.editasmedicine.com/about/?utm_source=openai)) 从竞争角度来看，Editas 所在的领域竞争激烈，研发壁垒高，临床和监管风险大。其差异化优势在于深厚的 CRISPR 专业知识以及日益增长的对体内基因编辑的战略重视。管理层强调了 EDIT-401 令人鼓舞的临床前证据，包括在非人灵长类动物中显著降低 LDL-C，这支持了该项目作为大型心脏代谢市场中同类首创或同类最佳竞争者的潜力。([ir.editasmedicine.com](https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-first-quarter-2026-results-and?utm_source=openai)) 近期发展至关重要。在2026年第一季度，Editas 表示仍有望在2026年中期提交 EDIT-401 的 IND 或 CTA 申请，并预计在2026年底前获得初步的人体概念验证数据。公司还在2026年春季的科学会议上展示了新的 EDIT-401 临床前数据。此外，Editas 报告了其 CRISPR 专利纠纷中一项有利的程序性进展，美国专利商标局重申了 Broad Institute 在涉及 CRISPR/Cas9 权利的干扰程序中的先前胜利。因此，对于投资者而言，Editas 是一家具有显著上行选择权的投机性生物技术公司，但其仍依赖于临床进展、监管执行和知识产权结果。([ir.editasmedicine.com](https://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-announces-first-quarter-2026-results-and?utm_source=openai))
